These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

258 related articles for article (PubMed ID: 9445322)

  • 41. Acute intravenous--intra-arterial revascularization therapy for severe ischemic stroke.
    Hill MD; Barber PA; Demchuk AM; Newcommon NJ; Cole-Haskayne A; Ryckborst K; Sopher L; Button A; Hu W; Hudon ME; Morrish W; Frayne R; Sevick RJ; Buchan AM
    Stroke; 2002 Jan; 33(1):279-82. PubMed ID: 11779923
    [TBL] [Abstract][Full Text] [Related]  

  • 42. [Intravenous tissue plasminogen activator (t-PA) for acute ischemic stroke in a local university hospital].
    Takahashi K; Iijima K; Oguro H; Bokura H; Nagai A; Yamaguchi S; Kobayashi S
    No To Shinkei; 2005 Aug; 57(8):683-8. PubMed ID: 16146212
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Intravenous tissue plasminogen activator for acute ischemic stroke: A Canadian hospital's experience.
    Chapman KM; Woolfenden AR; Graeb D; Johnston DC; Beckman J; Schulzer M; Teal PA
    Stroke; 2000 Dec; 31(12):2920-4. PubMed ID: 11108749
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Intraarterial thrombolytic therapy within 3 hours of the onset of stroke.
    Bourekas EC; Slivka AP; Shah R; Sunshine J; Suarez JI
    Neurosurgery; 2004 Jan; 54(1):39-44; discussion 44-6. PubMed ID: 14683539
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Is intra-arterial thrombolysis safe after full-dose intravenous recombinant tissue plasminogen activator for acute ischemic stroke?
    Shaltoni HM; Albright KC; Gonzales NR; Weir RU; Khaja AM; Sugg RM; Campbell MS; Cacayorin ED; Grotta JC; Noser EA
    Stroke; 2007 Jan; 38(1):80-4. PubMed ID: 17122433
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Alteplase at 0.6 mg/kg for acute ischemic stroke within 3 hours of onset: Japan Alteplase Clinical Trial (J-ACT).
    Yamaguchi T; Mori E; Minematsu K; Nakagawara J; Hashi K; Saito I; Shinohara Y;
    Stroke; 2006 Jul; 37(7):1810-5. PubMed ID: 16763187
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Safety of air medical transportation after tissue plasminogen activator administration in acute ischemic stroke.
    Chalela JA; Kasner SE; Jauch EC; Pancioli AM
    Stroke; 1999 Nov; 30(11):2366-8. PubMed ID: 10548672
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Transition of European Cooperative Acute Stroke Study III results to clinical practice: ninety-day outcomes in a US cohort.
    Cronin CA; Langenberg P; Dutta TM; Kittner SJ
    Stroke; 2013 Dec; 44(12):3544-6. PubMed ID: 24092551
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Two tales: hemorrhagic transformation but not parenchymal hemorrhage after thrombolysis is related to severity and duration of ischemia: MRI study of acute stroke patients treated with intravenous tissue plasminogen activator within 6 hours.
    Thomalla G; Sobesky J; Köhrmann M; Fiebach JB; Fiehler J; Zaro Weber O; Kruetzelmann A; Kucinski T; Rosenkranz M; Röther J; Schellinger PD
    Stroke; 2007 Feb; 38(2):313-8. PubMed ID: 17204683
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Comparison of tissue plasminogen activator administration management between Telestroke Network hospitals and academic stroke centers: the Telemedical Pilot Project for Integrative Stroke Care in Bavaria/Germany.
    Audebert HJ; Kukla C; Vatankhah B; Gotzler B; Schenkel J; Hofer S; Fürst A; Haberl RL
    Stroke; 2006 Jul; 37(7):1822-7. PubMed ID: 16763192
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Role of tissue plasminogen activator in acute ischemic stroke.
    Hatcher MA; Starr JA
    Ann Pharmacother; 2011 Mar; 45(3):364-71. PubMed ID: 21386027
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Perfusion computed tomography-guided intravenous thrombolysis for acute ischemic stroke beyond 4.5 hours: a case-control study.
    García-Bermejo P; Calleja AI; Pérez-Fernández S; Cortijo E; del Monte JM; García-Porrero M; Fe Muñoz M; Fernández-Herranz R; Arenillas JF
    Cerebrovasc Dis; 2012; 34(1):31-7. PubMed ID: 22759450
    [TBL] [Abstract][Full Text] [Related]  

  • 53. An open, multicenter trial of recombinant tissue plasminogen activator in acute stroke. A progress report. The rt-PA Acute Stroke Study Group.
    del Zoppo GJ
    Stroke; 1990 Dec; 21(12 Suppl):IV174-5. PubMed ID: 2124386
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Tissue plasminogen activator for acute ischemic stroke in clinical practice: a meta-analysis of safety data.
    Graham GD
    Stroke; 2003 Dec; 34(12):2847-50. PubMed ID: 14605319
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Thrombolytic treatment of acute ischemic stroke.
    Meschia JF; Miller DA; Brott TG
    Mayo Clin Proc; 2002 Jun; 77(6):542-51. PubMed ID: 12059124
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Ten-Year Evaluation of the TOYOTA Prehospital Stroke Scale for Tissue Plasminogen Activator Intravenous Therapy in the Real World.
    Suzuki J; Nakai N; Kondo N; Tsuji H; Inagaki R; Furukawa S; Iwata M; Nishida S; Ito Y
    Cerebrovasc Dis; 2018; 46(3-4):184-192. PubMed ID: 30384371
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Drip-and-Ship Thrombolytic Therapy for Acute Ischemic Stroke.
    Deguchi I; Mizuno S; Kohyama S; Tanahashi N; Takao M
    J Stroke Cerebrovasc Dis; 2018 Jan; 27(1):61-67. PubMed ID: 28867523
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Should thrombolytic therapy be the first-line treatment for acute ischemic stroke? t-PA--the best current option for most patients.
    Grotta J
    N Engl J Med; 1997 Oct; 337(18):1310-3. PubMed ID: 9345085
    [No Abstract]   [Full Text] [Related]  

  • 59. [Intravenous thrombolytic treatment in acute ischemic stroke: initial results in the Complejo Hospitalario Universitario de Albacete].
    García-García J; Gracia-Gil J; Sopelana-Garay D; Ayo-Martín O; Vadillo-Bermejo A; Touza B; Peñalver-Pardines C; Zorita MD; Segura T
    Rev Neurol; 2008 Jan 1-15; 46(1):7-12. PubMed ID: 18214820
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Combination Therapy Stroke Trial: recombinant tissue-type plasminogen activator with/without lubeluzole.
    Grotta J;
    Cerebrovasc Dis; 2001; 12(3):258-63. PubMed ID: 11641593
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.